antibody

Mouse monoclonal antibody Anti-Human RUNX1

MBS120097

0.1 mg

345 USD

monoclonal

mouse

nonconjugated

RUNXA3B6

western blot, dot blot

Antibody

Mouse monoclonal antibody Anti-Human RUNX1

RUNX1

Homo sapiens runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) (RUNX1), transcript variant 1, mRNA; AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB;AML1-EVI-1

Homo sapiens runt-related transcription factor 1 (RUNX1), transcript variant 1, mRNA; Runt-related transcription factor 1; runt-related transcription factor 1; AML1-EVI-1 fusion protein; CBF-alpha-2; PEA2-alpha B; PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit; acute myeloid leukemia 1 protein; core-binding factor, runt domain, alpha subunit 2; oncogene AML-1; polyomavirus enhancer-binding protein 2 alpha B subunit; runt-related transcription factor 1; Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit

RUNX1

RUNX1; RUNX1; AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; AML1-EVI-1

RUNX1_HUMAN

Monoclonal

IgG1

RUNXA3B6

Mouse

Human

5967

100 ug/ml (1.0 ml)

Dot Blot (DB)

Preparation: This antibody was purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum.

Sterility: Filtered through a 0.22 um membrane.

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Two transcript variants encoding different isoforms have been found for this gene. [NCBI Entrez Gene Summary]

169790829

NP_001745.2

NM_001754

37,733 Da

Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Chronic Myeloid Leukemia Pathway (83116); Chronic Myeloid Leukemia Pathway (528); Pathways In Cancer (83105); Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987)

Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

AML1: CBF binds to the core site, 5 -PYGPYGGT-3 , of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1. Interacts with YAP1. Interacts with HIPK2. Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity. Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. 11 isoforms of the human protein are produced by alternative splicing. Protein type: DNA-binding; Oncoprotein; Transcription factor. Chromosomal Location of Human Ortholog: 21q22.3. Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; basement membrane; nucleus. Molecular Function: protein binding; protein homodimerization activity; DNA binding; protein heterodimerization activity; calcium ion binding; transcription factor activity; transcription factor binding; ATP binding. Biological Process: hair follicle morphogenesis; central nervous system development; transcription, DNA-dependent; in utero embryonic development; embryonic hemopoiesis; positive regulation of transcription, DNA-dependent; positive regulation of granulocyte differentiation; regulation of signal transduction; liver development; negative regulation of granulocyte differentiation; peripheral nervous system neuron development; behavioral response to pain; positive regulation of angiogenesis; myeloid progenitor cell differentiation; positive regulation of interleukin-2 production; myeloid cell differentiation; positive regulation of transcription from RNA polymerase II promoter; hemopoiesis; skeletal development. Disease: Platelet Disorder, Familial, With Associated Myeloid Malignancy; Leukemia, Acute Myeloid; Rheumatoid Arthritis

0.1 mg

345 USD